Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Cosentyx in adults with active moderate to severe hidradenitis suppurativa.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis to present Kisqali Phase III NATALEE trial data at ASCO
- Bristol-Myers adds new U.S. manufacturing facility for viral vector production
- Novartis announces results from Phase III APPOINT-PNH trial of iptacopan
- Novartis upgraded to Buy from Hold at Deutsche Bank
- Novartis raises FY23 group sales view to ‘mid-single digits’ from ‘low-to-mid’
